| 研究成果： |
主持、参与或执行的科研项目： 1. 长春百克生物科技股份公司、2023220103000107、肿瘤治疗性RNA疫苗的研发、2023.12.-2025.06、120万元、主持、在研 2.吉林省科技厅、20230101167JC、靶向DCs的多靶点RNA复制子肿瘤疫苗研究、2023.01-2025.12、10万元、主持、在研 3.吉林省教育厅、JJKH20231142KJ、肿瘤mRNA疫苗与人参皂苷的协调抗肿瘤机制研究、2023.01-2024、2.5万元、主持、在研 4.“十三五”国家科技重大专项，2018ZX09301050-003、创新肿瘤治疗性疫苗的研发、2018.06-2020.12、183.85 万元、主持； 5. 吉林省科技厅，20160519018JH、吉林省新型肿瘤疫苗研究创新团队、2016.01-2018.12，20万元、参与、在研； 6. “十二五”国家科技重大专项，2014ZX09304314-001、以survivin和MUC1为靶点重组腺病毒载体肿瘤治疗性疫苗的临床前研究、164.47万、执行、已结题； 7. 国家自然基金青年项目，31300765、以 MUC1 VNTR、survivin和FAP-α为靶点的自组装纳米载体基因疫苗抗肿瘤作用机制研究、2014/01-2016/12、23万元、主持、已结题； 8. 长春百克生物科技股份公司、肿瘤治疗性疫苗的研究、2012-2019、120万元、主持、在研， 9. 吉林省科技发展计划，20130522006JH、双基因自组装纳米载体肿瘤疫苗研究、2013.01-2015.12、3万元、主持、已结题； 10. 教育部新教师基金，20120061120025、针对肿瘤微环境及肿瘤细胞的三基因肿瘤疫苗作用机制研究、2013.01-201 5.12、4万元、主持、已结题； 11. 吉林省产业技术研究与开发专项项目，2013C014-3、肺癌早期基因诊断技术的研究与开发、2013/01 - 2014/12、10万元、参与、已结题； 12. 吉林大学基本科研业务费，450060323260、以 survivin和MUC1 VNTRs 为靶点的肿瘤基因疫苗免疫佐剂的效果研究、2011/01-2012/12、2万元、主持、已结题； 13. 吉林大学交叉学科项目，200903255、以 survivin和MUC1 VNTRs 为靶点的肿瘤基因疫苗异源prime - boost免疫策略的研究、2009/12-2011/01、5万元、主持、已结题。 代表性文章
1. Ke Zhang, QimugeWuri, Zongyu Cai, Xueli Qu, Shiqi Zhang, Hui Wu, Jiaxin Wu, Chu Wang, Xianghui Yu, Wei Kong, and Haihong Zhang*, The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model, Int J Mol Sci., 2024 Feb 4;25(3):1880. doi: 10.3390/ijms25031880. 2. , , , , , , , , , , , , , , , *. Metformin improved a heterologous prime-boost of dual-targeting cancer vaccines to inhibit tumor growth in a melanoma mouse model. Int Immunopharmacol. 2024 Feb 15:128:111431. 3. Fang-Fang Zhang, Yu Xie, Qianqian Guo, Ping Xu, Chenlu Liu, Fei Geng, Zhenzhen Lu, Hui Wu, Bin Yu, Jia-Xin Wu, Wei Kong, Xiang-Hui Yu, Hai-Hong Zhang*. Epitope-based minigene vaccine targeting fibroblast activation protein α can induce specific immune responses and anti-tumor effects in the 4T1 murine breast cancer model, International Immunopharmacology, 2022 Nov;112:109237. doi: 10.1016/j. intimp. 2022. 109237. 4. Fei Geng, Ling Dong, Xin Bao, Qianqian Guo, Jie Guo, Yi Zhou, Bin Yu, Hui Wu, Jiaxin Wu, Haihong Zhang*, Xianghui Yu*, and Wei Kong, CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer. Molecular Therapy-Oncolytics, 2022 Jul 31;26:304-313. 5. Fei Geng, Ling Dong, Xin Bao, Qianqian Guo, Jie Guo, Yi Zhou, Bin Yu, Hui Wu, Jiaxin Wu, Haihong Zhang*, Xianghui Yu*, and Wei Kong, CAFs/tumor cells co-targeting DNA vaccine in combination with low-dose gemcitabine for the treatment of Panc02 murine pancreatic cancer. Molecular Therapy-Oncolytics, accepted.
6. Dong L, Feng M, Qiao Y, Liu C, Zhou Y, Xing S, Zhang K, Cai Z, Wu H, Wu J, Yu X, Zhang H*, Kong W*. Preclinical Safety and Biodistribution in Mice Following Single-Dose Intramuscular Inoculation of Tumor DNA Vaccine by Electroporation. Hum Gene Ther. 2022 Jul; 33 (13-14):757-764. 7. Liu C, Cong X, Wang Y, Guo Q, Xie Y, Geng F, Guo J, Dong L, Zhou Y, Wu H, Yu B, Wu J, Zhang H*, Yu X*, Kong W. Fast DNA Vaccination Strategy Elicits a Stronger Immune Response Dependent on CD8+CD11c+ Cell Accumulation. Front Oncol. 2021 Dec 7; 11 : 752444. 8. Qianqian Guo, Lizheng Wang, Ping Xu, Fei Geng, Jie Guo, Ling Dong, Xin Bao, Yi Zhou, Mengfan Feng, Jiaxin Wu, Hui Wu, Bin Yu, Haihong Zhang*, Xianghui Yu, Wei Kong*. Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse. Oncoimmunology. 2020 Nov 9; 9 (1) : 1841392. 9. Fei Geng, Xin Bao, Ling Dong, Qian-Qian Guo, Jie Guo, Yu Xie, Yi Zhou, Bin Yu, Hui Wu, Jia-Xin Wu, Hai-Hong Zhang*, Xiang-Hui Yu*, Wei Kong. Doxorubicin Pretreatment Enhances FAPα/survivin Co-Targeting DNA Vaccine Anti-Tumor Activity Primarily Through Decreasing Peripheral MDSCs in the 4T1 Murine Breast Cancer Model.Oncoimmunology. 2020 Apr 16;9(1):1747350. 10. Fei Geng, Jie Guo, Qian-Qian Guo, Yu Xie, Ling Dong, Yi Zhou, Chen-Lu Liu, Bin Yu, Hui Wu, Jia-Xin Wu, Hai-Hong Zhang*, Wei Kong*, Xiang-Hui Yu*. A DNA vaccine expressing an optimized secreted FAPα induces enhanced anti-tumor activity by altering the tumor microenvironment in a murine model of breast cancer. Vaccine 2019,37(31):4382-4391. 11. Chenlu Liu, Zhenzhen Lu, Yu Xie, Qianqian Guo, Fei Geng, Bo Sun, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu, Wei Kong, Haihong Zhang*, Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect. Immunology letter. 2018 Jun 9; 200:33-42. 12. Chenlu Liu, Yu Xie, Bo Sun, Fei Geng, Fangfang Zhang, Qianqian Guo, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu, Wei Kong, Haihong Zhang*.MUC1- and survivin - based DNA vaccine combining immunoadjuvants CpG and interleukin 2 in bicistronic expression plasmid generates specific immune responses and anti-tumor effects in a murine colorectal carcinoma modelScand J Immunol. 2018 Feb; 87 (2):63-72. 13. Qiu Xia, Fei Geng, Fang-Fang Zhang, Chen-Lu Liu, Ping Xu, Zhen-Zhen Lu, Yu Xie, Hui Wu，Bo , Wei Kong, Xiang-Hui Yu, Hai-Hong Zhang*. Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma.Immunopharmacol Immunotoxicol. 2017 Feb;39(1):37-44. 14. Qiu Xia, Fang-Fang Zhang, Fei Geng, Chen-Lu Liu, Yu-Qian Wang, Ping Xu, Zhen-Zhen Lu, Yu Xie, Hui Wu, Yan Chen, Yong Zhang, Wei Kong, Xiang-Hui Yu, Hai-Hong Zhang*, Improvement of anti-tumor immunity of fibroblast activation protein a based vaccines by combination with cyclophosphamide in a murine model of breast cancer.Cellular Immunology. 2016 Dec; 310:89-98. 15. Qiu Xia, Fei Geng, Fang-Fang Zhang, Chen-Lu Liu, Ping Xu, Zhen-Zhen Lu, Bin Yu, Hui Wu, Jia-Xin Wu, Hai-Hong Zhang*, Wei Kong, Xiang-Hui Yu.Enhancement of FAPα-targeted immunotherapy and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice. Vaccine. 2016 Aug 31; 34(38): 4526-35. 16. Haihong Zhang, Chenlu Liu, Qiu Xia, Zhenzhen Lu, Ping Xu, Fangfang Zhang, Fei Geng, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu*, and Wei Kong*，MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model. Vaccine. 2016 May 23; 34(24):2648-55. 17. Qiu Xia, Fang‑Fang Zhang, Fei Geng, Chen‑Lu Liu, Ping Xu, Zhen‑Zhen Lu, Bin Yu, Hui Wu, Jia‑Xin Wu, Hai‑Hong Zhang*, Wei Kong, Xiang‑Hui Yu. Anti‑tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model.Cancer Immunology Immunotherapy. 2016 May; 65(5):613-24. doi: 10.1007/s00262-016-1827-4. 18. YuQian Wang, Chenlu Liu, Qiu Xia, Wang Peng, Bo Li, Zhenzhen Lu, Jiaxi Sun, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu, Wei Kong, HaiHong Zhang* and Xianling Cong*. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs. Oncol Rep.2014 Mar;31(3):1437-44. 19. Hui Wu#, Haihong Zhang#, Yue Hu, Qiu Xia, Chenlu Liu, Yingnan Li, Bin Yu, Tiejun Gu, Xizhen Zhang, Xianghui Yu,* and Wei Kong,*.Sphere Formation Assay is Not an Effective Method for Cancer Stem Cell Derivation and Characterization from the Caco-2 Colorectal Cell Line. Curr Stem Cell Res Ther. 2014 Mar; 9(2):82-8. 20. Hui Wu,† Haihong Zhang,† Peng Wang, Zhuo Mao, Li Feng, Yuqian Wang, Chenlu Liu, Qiu Xia, Bo Li, Heya Zhao, Yan Chen, Jiaxin Wu, Wei Kong,* Xianghui Yu*，Short-Form CDYLb but not long-form CDYLa functions cooperatively with histone methyltransferase G9a in hepatocellular carcinomas. Genes Chromosomes Cancer. 2013 Jul; 52(7):644-55. 21. Yu-Qian Wang1, Hai-Hong Zhang1, Chen-Lu Liu, Hui Wu, Peng Wang, Qiu Xia, Li-Xing Zhang, Bo Li, Jia-Xin Wu, Bin Yu, Tie-Jun Gu, Xiang-Hui Yu*, Wei Kong*. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. International Immunopharmacology.2013 Apr 25; 17(1):9-17. 22. Yu-Qian Wang&, Hai-Hong Zhang&, Chen-Lu Liu, Qiu Xia, Hui Wu, Xiang-Hui Yu*, Wei Kong*. Correlation between auto-antibodies to survivin and MUC1 VNTR in colorectal cancer. Asian Pacific Journal of Cancer Prevention. 2012, 13: 5557-62. 23. Haihong Zhang, Yuqian Wang, Chenlu Liu, Lixing Zhang, Qiu Xia, Yong Zhang, Jiaxin Wu, Chunlai Jiang, Yan Chen, Yongge Wu, Xiao Zha, Xianghui Yu* and Wei Kong*. DNA and Adenovirus Tumor Vaccine Expressing Truncated Survivin Generates Specific Immune Responses and Antitumor Effects in a Murine Melanoma Model. Cancer Immunology Immunotherapy. 2012，61:1857–1867 24. ZHANG Haihong, ZHANG Shuzi, YU Xianghui, KONG Wei*. Construction and Expression of Human Survivin and Preparation of Its Polyclonal Antibody. Chemical Research In Chinese Universities. 2008 24(6), 767-770.
专利 1. 以人源LIGHT截短型突变蛋白为基础的抗肿瘤的应用(申请号：202211381334.9)发明人：张海红；于湘晖；孔维；董玲；耿飞；郭杰
2. 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用(专利申请号：201911237825.4 ) 发明人：张海红；于湘晖；孔维；耿飞；郭杰。 3. 以序列优化的分泌形式的FAPα为基础的肿瘤DNA疫苗的应用(专利申请号：201910498855.4)，发明人：张海红；于湘晖；孔维；耿飞；郭杰 4. 以FAPα的CTL表位肽为基础的肽类疫苗和微基因疫苗的应用（专利号：ZL201711060548.5）, 发明人：张海红、于湘晖、孔维、张芳芳、刘晨露、徐平、耿飞、谢雨、郭倩倩、陆臻桢， 5. 以成纤维激活蛋白α为靶点的肿瘤DNA疫苗及病毒载体疫苗（专利号： ZL201610363126.4），发明人：张海红 于湘晖 孔维 夏秋 耿飞， 6. 以粘蛋白1和生存素为靶点的肿瘤DNA疫苗和病毒载体疫苗（专利号：ZL200910252427.x），发明人：孔维；张海红；于湘晖；于永慧 7. 以粘蛋白1和生存素为靶点的肿瘤基因工程疫苗（专利号：ZL201110086366.1），发明人：孔维 张海红 于湘晖 于永慧 王玉倩 张丽星 8. 以粘蛋白1和生存素为靶点的肿瘤DNA疫苗及病毒载体疫苗-分案（申请号:ZL201410189139.5），发明人：孔维；张海红；于湘晖；于永慧 9. 重组疫苗及其应用（申请号201711190257.8），发明人：孔维，张海红，于湘晖，陆臻桢，刘晨露，徐萍，耿飞，张芳芳，谢雨，郭倩倩 10. 国际专利名称：重组疫苗及其应用（申请号PCTCN2018116393，申请日：20181120 优先权日：2017.11.24），发明人：孔维，张海红，于湘晖，陆臻桢，刘晨露，徐萍，耿飞，张芳芳，谢雨，郭倩倩
|
